CHELMSFORD, Mass., Nov. 15, 2018 /PRNewswire/ -- Brooks Automation,
Inc. (Nasdaq: BRKS), a leading worldwide provider of automation and
cryogenic solutions for multiple markets including semiconductor
manufacturing and life sciences, announced today that it has closed
its previously announced acquisition of GENEWIZ Group.
GENEWIZ, headquartered in Plainfield,
New Jersey, is a leading provider of gene sequencing and
synthesis services for more than 4,000 institutional customers
worldwide and is supported by their global network of laboratories
spanning the United States,
China, Japan, Germany and the United Kingdom.
The Company will provide additional information on the GENEWIZ
business in their upcoming earnings call on November 19, 2018. Instructions for
listening to the call can be found at
www.brooks.com/company/investors.
About Brooks Automation, Inc.
Brooks is a leading worldwide provider of automation and
cryogenic solutions for multiple markets including semiconductor
manufacturing and life sciences. Brooks' technologies,
engineering competencies and global service capabilities provide
customers speed to market and ensure high uptime and rapid
response, which equate to superior value in their mission-critical
controlled environments. Since 1978, Brooks has been a
leading partner to the global semiconductor manufacturing market
and since 2011 Brooks has applied its automation and cryogenics
expertise to meet the sample storage needs of customers in the life
sciences industry. Brooks' life sciences offerings include a
broad range of products and services for on-site infrastructure for
sample management in ‑20°C to -190°C temperatures, as well as
comprehensive outsource service solutions across the complete life
cycle of biological samples including collection, transportation,
processing, storage, protection, retrieval and disposal.
Brooks is headquartered in Chelmsford,
MA, with operations in North
America, Europe and
Asia. For more information, visit www.brooks.com.
About GENEWIZ Group
GENEWIZ is a global provider of genomics services enabling
research scientists within pharmaceutical, biotechnology,
agriculture, environmental and clean energy, academic, and
government institutions to advance their discoveries. The
company was founded in 1999 by Dr. Steve
Sun and Dr. Amy Liao and
today serves over 4,000 customers globally. Customers rely on
the unique and proprietary genomics technologies and services
backed by GENEWIZ's specialized experts in Sanger sequencing, next generation sequencing,
gene synthesis, molecular biology, bioinformatics, and GLP
regulatory-compliant services. Headquartered in South Plainfield, NJ, GENEWIZ operates a
network of laboratories in Boston,
MA; Washington, D.C. Metro;
Research Triangle Park, NC;
San Diego, CA; San Francisco, CA; and Seattle, WA. International locations
include Beijing, Suzhou,
Tianjin, and Guangzhou, China; Takeley, United Kingdom; Leipzig, Germany; and Tokyo, Japan. For more information,
visit www.genewiz.com and follow them on LinkedIn, Twitter,
Facebook, YouTube, WeChat, and Weibo.
"Safe Harbor Statement" under Section 21E of the Securities
Exchange Act of 1934
Some statements in this release are forward-looking statements
made under Section 21E of the Securities Exchange Act of 1934.
These statements are neither promises nor guarantees but involve
risks and uncertainties, both known and unknown, that could cause
Brooks' financial and business results to differ materially from
our expectations. They are based on the facts known to management
at the time they are made. These forward-looking statements
include, but are not limited to, statements about the anticipated
benefits of the acquisition of GENEWIZ Group and the expected
future capabilities of the combined companies. Factors that could
cause results to differ from our expectations include the
following: unexpected costs, charges or expenses resulting from the
transaction; and potential adverse reactions or changes to business
relationships resulting from the announcement or completion of the
transaction. In addition, actual results are subject to other risks
that relate more broadly to Brooks' overall business, including
those that we have described in our filings with the Securities and
Exchange Commission, including but not limited to our Annual Report
on Form 10-K, current reports on Form 8-K and our quarterly reports
on Form 10-Q. As a result we can provide no assurance that our
future results will not be materially different from those
projected. Brooks expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to any such statement
to reflect any change in our expectations or any change in events,
conditions or circumstances on which any such statement is based.
Brooks undertakes no obligation to update the information contained
in this press release.
CONTACTS:
Sherry Dinsmore
Brooks Automation
978.262.2400
sherry.dinsmore@brooks.com
John Mills
Senior Managing Director
ICR, LLC
646.277.1254
john.mills@icrinc.com
View original
content:http://www.prnewswire.com/news-releases/brooks-automation-announces-completion-of-genewiz-acquisition-300751759.html
SOURCE Brooks Automation, Inc.